Cardiac Allograft Vasculopathy (CAV) is a disease which has a high prevalence in Heart transplant (HTx) patients. It is characterized by concentric thickening of the wall of the coronary artery of the transplanted heart. The pathogenesis of CAV is complex; various cell types from both the host and the donor play a role. Activation of immunological components affects the vasculature of the allograft. Although in the past a lot of knowledge is gained about the processes that underlie the pathogenesis of CAV, there are still gaps in our knowledge. By clarifying the exact roles of all these different components, a solution for CAV may come in reach. We have the unique opportunity to study allograft vasculopathy in hearts after transplantation, ...
Cardiac allograft vasculopathy (CAV) is a transplant pathology, limiting graft survival after heart ...
Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft failure af...
Abstract—Cardiac allograft vasculopathy (CAV) continues to limit the long-term success of cardiac tr...
Cardiac Allograft Vasculopathy (CAV) is a disease which has a high prevalence in Heart transplant (H...
Cardiac transplantation is currently the preferred choice of treatment for end-stage cardiac disease...
Introduction: Long-term survival after heart transplantation (HTx) is hampered by cardiac allograft ...
Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure after hea...
Item does not contain fulltextINTRODUCTION: Long-term survival after heart transplantation (HTx) is ...
Abstract Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure ...
Cardiac allograft vasculopathy (CAV) has a high prevalence among patients that have undergone heart ...
Abstract: Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft ...
Cardiac allograft vasculopathy (CAV) limits the long-term success of heart transplants. Generation o...
Jacob C Jentzer,1 Gavin W Hickey,1 Sameer J Khandhar2,3 1Heart and Vascular Institute, Universi...
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a multifactorial pathology limiting the survival...
Cardiac allograft vasculopathy (CAV) is a transplant pathology, limiting graft survival after heart ...
Cardiac allograft vasculopathy (CAV) is a transplant pathology, limiting graft survival after heart ...
Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft failure af...
Abstract—Cardiac allograft vasculopathy (CAV) continues to limit the long-term success of cardiac tr...
Cardiac Allograft Vasculopathy (CAV) is a disease which has a high prevalence in Heart transplant (H...
Cardiac transplantation is currently the preferred choice of treatment for end-stage cardiac disease...
Introduction: Long-term survival after heart transplantation (HTx) is hampered by cardiac allograft ...
Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure after hea...
Item does not contain fulltextINTRODUCTION: Long-term survival after heart transplantation (HTx) is ...
Abstract Cardiac allograft vasculopathy (CAV) is one of the main causes of late-stage heart failure ...
Cardiac allograft vasculopathy (CAV) has a high prevalence among patients that have undergone heart ...
Abstract: Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft ...
Cardiac allograft vasculopathy (CAV) limits the long-term success of heart transplants. Generation o...
Jacob C Jentzer,1 Gavin W Hickey,1 Sameer J Khandhar2,3 1Heart and Vascular Institute, Universi...
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a multifactorial pathology limiting the survival...
Cardiac allograft vasculopathy (CAV) is a transplant pathology, limiting graft survival after heart ...
Cardiac allograft vasculopathy (CAV) is a transplant pathology, limiting graft survival after heart ...
Cardiac allograft vasculopathy (CAV) remains one of the leading causes of death and graft failure af...
Abstract—Cardiac allograft vasculopathy (CAV) continues to limit the long-term success of cardiac tr...